Stockscreener 앱 받기
6.90
4.56%
-0.33
시간 외 거래:
6.89
-0.01
-0.14%
Solid Biosciences Inc 주식(SLDB)의 최신 뉴스
Invus and affiliates hold 9.99% of Solid Biosciences (NASDAQ: SLDB) via warrants and shares - Stock Titan
One new Solid Biosciences employee gets 8,070 stock units - Stock Titan
Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy - marketscreener.com
Solid Bio wins new buy at Guggenheim on lead asset - MSN
Solid Biosciences receives EU orphan drug status for SGT-003 - Investing.com UK
Solid Biosciences (SLDB) Receives Orphan Drug Designation for SG - GuruFocus
Solid Biosciences receives EU orphan drug status for SGT-003 By Investing.com - Investing.com South Africa
Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy - The Manila Times
EU grants orphan status to Solid’s Duchenne gene therapy candidate - Stock Titan
Solid Biosciences Announces Receipt of European Commission - GlobeNewswire
Solid Biosciences (NASDAQ:SLDB) Rating Increased to Strong-Buy at Truist Financial - MarketBeat
BlackRock (NASDAQ: SLDB) holds 4.7% of Solid Biosciences, 4.58M shares - Stock Titan
Solid Biosciences Inc. sponsors SADS Foundation symposium to back genetic heart rhythm research - Traders Union
Solid Biosciences announces $240 million private placement - MSN
Solid Biosciences Inc. commits to industry and advocacy collaboration on Duchenne - Traders Union
Solid Biosciences (NASDAQ: SLDB) seeks approval to double authorized shares at 2026 meeting - Stock Titan
Solid Biosciences (SLDB) COO earns 79,341 RSUs on performance milestone - Stock Titan
Solid Biosciences (NASDAQ: SLDB) CMO awarded 58,847 RSUs on milestone - Stock Titan
Solid Biosciences (SLDB) CEO earns 169,401 RSUs tied to PSUs - Stock Titan
Solid Biosciences (SLDB) CTO earns 54,925 RSUs on performance milestone - Stock Titan
Solid Biosciences (SLDB) CFO awarded 56,647 RSUs after performance milestone - Stock Titan
Solid Biosciences (NASDAQ: SLDB) awards 54,925 performance-based RSUs - Stock Titan
Piper Sandler Reaffirms Their Buy Rating on Solid Biosciences (SLDB) - The Globe and Mail
Solid Biosciences Inc. advances SGT-212 gene therapy for Friedreich ataxia into human trials - Traders Union
Piper Sandler Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $17 - Moomoo
Solid Biosciences Inc. to present new targeting strategies in gene therapy - Traders Union
Solid Biosciences (NASDAQ:SLDB) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Who Backs Solid Biosciences (SLDB) Stock (Modest Uptick) 2026-04-18Index Investing - Cổng thông tin điện tử Tỉnh Sơn La
Solid Biosciences Inc. (NASDAQ:SLDB) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Stryker (SYK), Solid Biosciences (SLDB) - The Globe and Mail
Needham Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $19 - Moomoo
Solid Biosciences (NASDAQ:SLDB) Sets New 12-Month HighHere's What Happened - MarketBeat
SLDB: Guggenheim Initiates Coverage with a 'Buy' Rating at $26 | - GuruFocus
Dow Update: Is Solid Biosciences Inc part of any ETF2026 Pullbacks & Low Risk Entry Point Guides - baoquankhu1.vn
Solid Biosciences (NASDAQ:SLDB) Stock Price Down 3.9%Here's Why - MarketBeat
Sell Signal: Can Solid Biosciences Inc maintain its current growth rate2026 Short Interest & Fast Moving Trade Plans - baoquankhu1.vn
Solid Biosciences reclassifies board member Ilan Ganot to Class I director - Investing.com Australia
Solid Biosciences Inc. Files Form 8-K with SEC Detailing Company Information and No Amendments as of April 10, 2026 - Minichart
Solid Biosciences (NASDAQ:SLDB) Raised to "Hold" at Wall Street Zen - MarketBeat
Solid Biosciences reclassifies board member Ilan Ganot to Class I director By Investing.com - Investing.com Australia
Solid Biosciences Adjusts Board Classes in Governance Move - TipRanks
Solid Biosciences (NASDAQ: SLDB) asks shareholders to double authorized shares to 480,000,000 - Stock Titan
Board reshuffle at Solid Biosciences (NASDAQ: SLDB) balances director classes - Stock Titan
Activity Recap: Can Solid Biosciences Inc maintain its current growth rateOil Prices & Long-Term Safe Return Strategies - baoquankhu1.vn
0.14%
0.48%
자본화:
|
볼륨(24시간):